IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat adv… Read more
Market Cap & Net Worth: IMMUNOCORE HLDGS ADS/1 (6YG)
IMMUNOCORE HLDGS ADS/1 (F:6YG) has a market capitalization of $1.35 Billion (€1.31 Billion) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #7305 globally and #777 in its home market, demonstrating a -7.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IMMUNOCORE HLDGS ADS/1's stock price €26.00 by its total outstanding shares 50530419 (50.53 Million).
IMMUNOCORE HLDGS ADS/1 Market Cap History: 2021 to 2026
IMMUNOCORE HLDGS ADS/1's market capitalization history from 2021 to 2026. Data shows change from $1.55 Billion to $1.35 Billion (-9.18% CAGR).
IMMUNOCORE HLDGS ADS/1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IMMUNOCORE HLDGS ADS/1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6YG by Market Capitalization
Companies near IMMUNOCORE HLDGS ADS/1 in the global market cap rankings as of March 19, 2026.
Key companies related to IMMUNOCORE HLDGS ADS/1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
IMMUNOCORE HLDGS ADS/1 Historical Marketcap From 2021 to 2026
Between 2021 and today, IMMUNOCORE HLDGS ADS/1's market cap moved from $1.55 Billion to $ 1.35 Billion, with a yearly change of -9.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.35 Billion | -12.75% |
| 2025 | €1.55 Billion | +8.76% |
| 2024 | €1.42 Billion | -55.08% |
| 2023 | €3.16 Billion | +15.09% |
| 2022 | €2.75 Billion | +77.85% |
| 2021 | €1.55 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of IMMUNOCORE HLDGS ADS/1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.35 Billion USD |
| MoneyControl | $1.35 Billion USD |
| MarketWatch | $1.35 Billion USD |
| marketcap.company | $1.35 Billion USD |
| Reuters | $1.35 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.